Mitochondrial Donation: An 18 Month Outcome Study.
Study Details
Study Description
Brief Summary
The Investigator proposes to record the fetal and postnatal development of children conceived using Mitochondrial Donation (MD) and to perform expert assessment of development at 18 months (corrected for gestational age) using the internationally validated Bayley-III developmental assessment tool.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
To record the fetal and postnatal development of children conceived using Mitochondrial Donation and to perform internationally validated Bayley-III developmental assessment tool at 18 months (corrected for gestational age).
The null hypothesis for this research is that children born following the use of Mitochondrial Donation (IVF) techniques have normal neurodevelopment developmental outcomes at 18 months.
Study Design
Outcome Measures
Primary Outcome Measures
- A normal neurodevelopmental quotient scored using a Bayley-III ( Bayley Scales of Infant and Toddler Development, Third Edition) at 18 months (corrected [18 months]
The Bayley Scale of Infant and Toddler Development, Third Edition (Bayley III) measures physical, motor, sensory, and cognitive development in babies and young children. The scale encompasses five developmental domains - cognitive, language, motor, social-emotional and adaptive behaviour. The structure of the Bayley-III Scales allows clinicians to administer each of the five scales (cognitive, language-receptive and expressive, motor-fine and gross, social-emotional, and adaptive behaviour) independent of others. Higher scores in each scale indicates more advanced development. Performance is summarised via scaled scores for each subtest, and composite scores for each scale, together with percentile ranks, developmental age equivalents, and growth scores. Discrepancy information is used to determine whether there are significant differences between a child's abilities in the domains measured, and how prevalent these differences are in the norming sample. A total score is not provided.
Secondary Outcome Measures
- 1)Normal hearing as assessed by formal audiology, [18 months]
Formal Audiology
- 2)Normal vision as assessed by ophthalmologist [18 months]
Ophthalmology Assessment
Eligibility Criteria
Criteria
Inclusion Criteria:
Women will only be eligible if they meet all of the following criteria.
-
Women with confirmed mtDNA mutation
-
Suitable to undergo Mitochondrial Donation as a treatment (in line with HFEA license)
-
Informed Consent for the study obtained before Mitochondrial Donation treatment commences
-
Ability and willingness to adhere to the protocol including evaluation schedule
-
Willingness to make available information collected during pregnancy, delivery and up to the child's age of 18 months (corrected for gestational age)
Exclusion Criteria:
Women will not be eligible if they meet any of the following criteria
-
Declined Mitochondrial Donation as a treatment (in line with HFEA license)
-
Inability or unwillingness to adhere to the protocol including evaluation schedule
-
Unwillingness to make available information collected during pregnancy, delivery and up to the child's age of 18 months (corrected for gestational age)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Newcastle upon Tyne Hospitals NHS Foundation Trust | Newcastle Upon Tyne | Tyne & Wear | United Kingdom | NE1 4LP |
Sponsors and Collaborators
- Newcastle-upon-Tyne Hospitals NHS Trust
- Wellcome Trust
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 8075